0.2470SEK-4.63%Mkt Cap: 199.81M SEKP/E: —Last update: 2026-05-13
Xintela AB (publ), a biopharma company, develops medical products in the field of stem cell therapy and targeted cancer therapy. The company's stem cell products include XSTEM, which is in Phase I/IIa clinical developmen…
Industry Peers
Biotechnologyloading…
Indicators:|
Key Statistics
Valuation
P/E (Trailing)—
P/E (Forward)—
PEG—
P/B-38.67
P/S87.56
EV/EBITDA-3.83
EV/Revenue77.39
EPS (TTM)-0.07
EPS (Forward)—
Cash Flow & Leverage
FCF Yield-12.69%
FCF Margin-1111.48%
Operating CF-41.62M SEK
CapEx (TTM)—
Net Debt/EBITDA0.50
Net Debt-23.21M SEK
Technical
SMA 500.2518 (-1.9%)
SMA 2000.3147 (-21.5%)
Beta2.02
S&P 52W Chg24.23%
Avg Vol (30d)335.39K
Avg Vol (10d)298.21K
Technical Indicators
RSI (14)47.5
MACD-0.0041
MACD Signal-0.0041
MACD Hist.-0.0000
BB Upper0.3008 SEK
BB Middle0.2573 SEK
BB Lower0.2138 SEK
BB Width33.79%
ATR (14)0.0241 SEK
Vol Ratio (20d)0.12x
52W Range
0.210011% of range0.5340
52W High0.5340 SEK
52W Low0.2100 SEK
Profitability
Gross Margin100.00%
EBITDA Margin0.00%
Profit Margin-2128.13%
Oper. Margin-3758.07%
ROE920.99%
ROA-167.32%
Revenue Growth-61.90%
Earnings Growth—
Balance Sheet
Debt/Equity-3.79
Current Ratio0.84
Quick Ratio0.79
Book Value/Sh-0.0060 SEK
Cash/Share0.0270 SEK
Dividends
Fwd Div Rate—
Trail. Div Rate0.0000 SEK
Div. Yield—
5Y Avg Yield—
Payout Ratio0.00%
Ex-Div Date—
Pay Date—
Ownership
Shares Out.861.27M
Float2.18M
Insiders9.44%
Institutions48.18%
Analyst Consensus
Rating—
Target (Mean)—
Target Range—
# Analysts—
Company
Market Cap199.81M SEK
Enterprise Value176.61M SEK
Revenue (TTM)2.28M SEK
Gross Profit2.28M SEK
Net Income (TTM)-48.56M SEK
Revenue/Share0.0030 SEK
Fiscal Year EndDec 2025
MR QuarterDec 2025
Employees—
Last Price0.2470 SEK
CountrySE
SectorHealthcare
IndustryBiotechnology
ISIN—